S&P 500   4,299.70 (+0.59%)
DOW   33,666.34 (+0.35%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.77%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.29%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.95%)
GE   112.33 (+1.30%)
DIS   80.13 (+0.29%)
AMC   7.78 (+2.78%)
PFE   32.08 (-0.06%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
S&P 500   4,299.70 (+0.59%)
DOW   33,666.34 (+0.35%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.77%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.29%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.95%)
GE   112.33 (+1.30%)
DIS   80.13 (+0.29%)
AMC   7.78 (+2.78%)
PFE   32.08 (-0.06%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
S&P 500   4,299.70 (+0.59%)
DOW   33,666.34 (+0.35%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.77%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.29%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.95%)
GE   112.33 (+1.30%)
DIS   80.13 (+0.29%)
AMC   7.78 (+2.78%)
PFE   32.08 (-0.06%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
S&P 500   4,299.70 (+0.59%)
DOW   33,666.34 (+0.35%)
QQQ   358.01 (+0.84%)
AAPL   170.69 (+0.15%)
MSFT   313.64 (+0.27%)
META   303.96 (+2.09%)
GOOGL   132.31 (+1.36%)
AMZN   125.98 (+0.00%)
TSLA   246.38 (+2.44%)
NVDA   430.89 (+1.46%)
NIO   8.91 (+5.32%)
BABA   85.54 (-0.77%)
AMD   102.76 (+4.78%)
T   15.01 (+0.94%)
F   12.56 (+1.29%)
MU   65.20 (-4.41%)
CGC   0.81 (-8.95%)
GE   112.33 (+1.30%)
DIS   80.13 (+0.29%)
AMC   7.78 (+2.78%)
PFE   32.08 (-0.06%)
PYPL   58.18 (+1.46%)
NFLX   376.36 (-0.33%)
NASDAQ:CDXS

Codexis (CDXS) Stock Forecast, Price & News

$1.70
+0.15 (+9.68%)
(As of 09/28/2023 ET)
Compare
Today's Range
$1.55
$1.71
50-Day Range
$1.50
$3.75
52-Week Range
$1.45
$6.98
Volume
862,466 shs
Average Volume
878,278 shs
Market Capitalization
$118.66 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.83

Codexis MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
362.1% Upside
$7.83 Price Target
Short Interest
Healthy
3.44% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-3.67
Upright™ Environmental Score
News Sentiment
0.84mentions of Codexis in the last 14 days
Based on 4 Articles This Week
Insider Trading
Acquiring Shares
$55,403 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.96) to ($0.69) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.46 out of 5 stars

Medical Sector

256th out of 975 stocks

Industrial Organic Chemicals Industry

5th out of 19 stocks


CDXS stock logo

About Codexis (NASDAQ:CDXS) Stock

Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.

CDXS Price History

CDXS Stock News Headlines

Codexis (NASDAQ:CDXS) Raised to "Hold" at StockNews.com
Codexis (NASDAQ:CDXS) Lowered to Sell at StockNews.com
Unlock the treasure on Mount Olympus with this little-known mining stock.
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
Codexis Stock Climbs After Executives Buy Up Shares
Unlock the treasure on Mount Olympus with this little-known mining stock.
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
Codexis (NASDAQ: CDXS)
Codexis Reports Second Quarter 2023 Financial Results
Codexis streamlining operations, reducing headcount
Craig-Hallum Keeps Their Buy Rating on Codexis (CDXS)
See More Headlines
Receive CDXS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Codexis and its competitors with MarketBeat's FREE daily newsletter.

CDXS Company Calendar

Last Earnings
8/03/2023
Today
9/28/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Industrial organic chemicals
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:CDXS
CUSIP
19200510
Employees
248
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$7.83
High Stock Price Forecast
$14.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+376.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
6 Analysts

Profitability

Net Income
$-33,590,000.00
Pretax Margin
-57.04%

Debt

Sales & Book Value

Annual Sales
$138.59 million
Book Value
$2.20 per share

Miscellaneous

Free Float
65,406,000
Market Cap
$114.82 million
Optionable
Optionable
Beta
1.79
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Dr. Stephen George Dilly MBBS (Age 63)
    Ph.D., Pres, CEO & Director
    Comp: $753.61k
  • Mr. Kevin Norrett M.B.A. (Age 50)
    M.S., Chief Operating Officer
    Comp: $507.28k
  • Ms. Margaret Fitzgerald J.D. (Age 52)
    Chief Legal and Compliance Officer, Gen. Counsel & Sec.
    Comp: $300.03k
  • Mr. Sriram Ryali M.B.A. (Age 41)
    Chief Financial Officer
  • Carrie McKim
    Director of Investor Relations
  • Ms. Karen Frechou-Armijo
    Sr. VP & Head of HR
  • Dr. Stefan Lutz Ph.D.
    Sr. VP of Research
  • Mr. Robert Sato M.B.A.
    Ph.D., Sr. VP of Pharmaceutical Devel., Quality & Regulatory













CDXS Stock - Frequently Asked Questions

Should I buy or sell Codexis stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Codexis in the last twelve months. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" CDXS shares.
View CDXS analyst ratings
or view top-rated stocks.

What is Codexis' stock price forecast for 2023?

6 Wall Street analysts have issued 1 year target prices for Codexis' shares. Their CDXS share price forecasts range from $4.00 to $14.00. On average, they anticipate the company's share price to reach $7.83 in the next twelve months. This suggests a possible upside of 376.2% from the stock's current price.
View analysts price targets for CDXS
or view top-rated stocks among Wall Street analysts.

How have CDXS shares performed in 2023?

Codexis' stock was trading at $4.66 at the start of the year. Since then, CDXS stock has decreased by 64.7% and is now trading at $1.6450.
View the best growth stocks for 2023 here
.

When is Codexis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our CDXS earnings forecast
.

How were Codexis' earnings last quarter?

Codexis, Inc. (NASDAQ:CDXS) released its quarterly earnings data on Thursday, August, 3rd. The biotechnology company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.04. The biotechnology company earned $21.32 million during the quarter, compared to analyst estimates of $19.83 million. Codexis had a negative net margin of 57.22% and a negative trailing twelve-month return on equity of 41.33%. The business's revenue was down 44.5% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.04) earnings per share.

What ETFs hold Codexis' stock?

ETFs with the largest weight of Codexis (NASDAQ:CDXS) stock in their portfolio include Jacob Forward ETF (JFWD), Invesco Nasdaq Future Gen 200 ETF (QQQS) and ARK Genomic Revolution ETF (ARKG).Inspire Small/Mid Cap ETF (ISMD).

What guidance has Codexis issued on next quarter's earnings?

Codexis updated its earnings guidance on Monday, July, 24th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $21.00 million-$22.00 million, compared to the consensus revenue estimate of $18.09 million.

What is John J. Nicols' approval rating as Codexis' CEO?

25 employees have rated Codexis Chief Executive Officer John J. Nicols on Glassdoor.com. John J. Nicols has an approval rating of 68% among the company's employees.

What other stocks do shareholders of Codexis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Codexis investors own include Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), AbbVie (ABBV), Micron Technology (MU), Enphase Energy (ENPH), Intellia Therapeutics (NTLA), NVIDIA (NVDA), OPKO Health (OPK) and Antares Pharma (ATRS).

What is Codexis' stock symbol?

Codexis trades on the NASDAQ under the ticker symbol "CDXS."

Who are Codexis' major shareholders?

Codexis' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (9.46%), Baillie Gifford & Co. (9.20%), ARK Investment Management LLC (6.18%), Nuveen Asset Management LLC (2.58%), Geode Capital Management LLC (1.92%) and State Street Corp (1.82%). Insiders that own company stock include Bernard J Kelley, Byron L Dorgan, Dennis P Wolf, John J Nicols, Kevin Norrett, Margaret Nell Fitzgerald, Patrick Y Yang, Sriram Ryali and Stephen George Dilly.
View institutional ownership trends
.

How do I buy shares of Codexis?

Shares of CDXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Codexis' stock price today?

One share of CDXS stock can currently be purchased for approximately $1.65.

How much money does Codexis make?

Codexis (NASDAQ:CDXS) has a market capitalization of $114.82 million and generates $138.59 million in revenue each year. The biotechnology company earns $-33,590,000.00 in net income (profit) each year or ($0.85) on an earnings per share basis.

How many employees does Codexis have?

The company employs 248 workers across the globe.

How can I contact Codexis?

Codexis' mailing address is 200 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063. The official website for the company is www.codexis.com. The biotechnology company can be reached via phone at (650) 421-8100, via email at ir@codexis.com, or via fax at 650-421-8102.

This page (NASDAQ:CDXS) was last updated on 9/28/2023 by MarketBeat.com Staff

My Account -